Hims & Hers shares crater as Novo Nordisk files a lawsuit against the telehealth firm. BofA analysts see significant further downside in HIMS stock.
Investors had little time to celebrate Eli Lilly's huge post-earnings gain. While Hims & Hers Health knocked shares down, LLY remains a healthcare stalwart.
Volatility returned to markets yesterday, triggering a tech rout. Among the unusually active options on Thursday were 278 calls and puts with Vol/OI ratios of 15 or higher. Among them, these 3 stocks offer...
Eli Lilly surges past the trillion-dollar mark as aggressive manufacturing expansion drives volume growth that eclipses rival Novo Nordisk in 2026.
Novo Nordisk stock sank as management forecasts decelerating growth in 2026. But should you treat this selloff in NVO shares as a buying opportunity? Let’s find out.
Markets enter February following a volatile final trading day of January that saw investors grappling with hotter-than-expected inflation data alongside news of a new Federal Reserve chair nominee.
Novo Nordisk entered 2026 with fresh momentum after the U.S. launch of its oral Wegovy pill. Is the stock a buy now?
As weight loss drugs move from injections to pills, this thematic ETF provides broad exposure for investors looking to profit from the industry’s next leg up.
After tanking on Novo's "Wegovy Pill" release, Eli Lilly shares reversed course. See why investors may like its acquisition of Ventyx Biosciences.
Track healthcare’s 2026 setup: GLP-1 drug adoption, a valuation gap vs. tech, and why VHT offers broad exposure with low fees and dividends.